期刊文献+

重组人血小板生成素对肿瘤化疗后血小板计数的影响 被引量:3

Effect of rhTPO on thrombocytopenia caused by chemotherapy
下载PDF
导出
摘要 目的 :观察重组人血小板生成素 (rhTPO )对肿瘤化疗后血小板降低的影响。方法 :选择以往肿瘤化疗后血小板小于 6 0× 10 9·L- 1的病人 (共 9例 ,其中淋巴瘤 7例 ,肺癌 2例 ,男性 4例 ,女性 5例。)予相似的化疗方案 ,在化疗结束后 2 4h内开始使用rhTPO(1.0 μg·kg- 1·d- 1,皮下注射 ) ,比较使用与不使用rhTPO病人血小板恢复情况。结果 :化疗后使用与不使用rhTPO血小板最低值分别为 (2 6±s 2 8)× 10 9·L- 1,(33± 30 )× 10 9·L- 1,P >0 .0 5。血小板最高值分别为 (2 0 3± 84 )× 10 9·L- 1,(110±76 )× 10 9·L- 1,P <0 .0 5。输注血小板的数量分别为 (0 .3± 0 .5 )U ,(0 .7± 0 .9)U ,P >0 .0 5。结论 :rhTPO未能减少化疗后血小板的下降程度 。
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2004年第1期56-58,共3页 Chinese Journal of New Drugs and Clinical Remedies
关键词 临床试验 血小板减少 药物疗法 重组人血小板生成素 clinical trials thrombocytopenia drug therapy carcinoma recombinant human thrombopoietin
  • 相关文献

参考文献7

  • 1[1]KAUSHANSKY K. Thrombopoietin[J]. N Engl J Med ,1998,339(11):746-754.
  • 2[2]BORGE OJ, RAMSFJELL V, VEIBY OP, et al. Thrombopoietin, but not erythropoietin promotes viability and inhibits apoptosis of multipotent murine hematopoietic progenitor cells in vitro[J]. Blood, 1996, 88(8):2859-2870.
  • 3[3]VADHAN-RAJ S. Recombinant human thrombopoietin in myelosuppressive chemotherapy[J]. Oncology(Huntingt), 2001,15(7 Suppl 8):35-38.
  • 4[4]MURRAY LJ,LUENS KM, ESTRADA MF, et al. Thrombopoietin mobilizes CD34+ cell subsets into peripheral blood and expands multilineage progenitors in bone marrow of cancer patients with normal hematopoiesis[J]. Exp Hematol, 1998, 26(3):207-216.
  • 5[5]VADHAN-RAJ S. Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia[J]. Semin Hematol, 2000, 37(2 Suppl 4):28-34.
  • 6[6]SITNICKA E,LIN N, PRIESTLEY GV, et al. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells[J]. Blood, 1996, 87(12):4998-5005.
  • 7[1]-[6] See above

同被引文献22

  • 1赵永强,王庆余,翟明,徐健,陈协群,刘文励,张梅,宋善俊,王健民,孟凡义,单渊东.重组人血小板生成素治疗慢性难治性特发性血小板减少性紫癜的多中心临床试验[J].中华内科杂志,2004,43(8):608-610. 被引量:102
  • 2吴秋玲,何静,陈燕,宋善俊.重组人血小板生成素治疗慢性难治性特发性血小板减少性紫癜的临床研究[J].华中科技大学学报(医学版),2004,33(3):297-299. 被引量:13
  • 3范磊,阮长耿.特发性血小板减少性紫癜发病机制[J].江苏医药,2006,32(4):357-359. 被引量:22
  • 4侯明,秦平.免疫性血小板减少性紫癜的诊断及治疗[J].中国实用内科杂志,2006,26(4):489-492. 被引量:28
  • 5RODEGHIERO F, STASI R, GERNSHEIMER T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group[J]. Blood, 2009, 113 ( 11 ) : 2386-2393.
  • 6KUTER DJ, BUSSEL JB, LYONS RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial[J]. Lancet, 2008, 371 (9610) : 395-403.
  • 7KOSUGI S, KURATA Y, TOMIYAMA Y, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura[J]. Br J Haematol, 1996, 93(3) : 704-706.
  • 8yon dem BORNE A, FOLMAN C, van den OUDENRIJN S, et al. The potential role of thrombopoietin in idiopathic thrombocytopenic purpura [J]. Blood Rev, 2002, 16(1 ): 57-59.
  • 9VADHAN-RAJ S, MURRAY LJ mulation of megakaryocyte and BUESO-RAMOS C, et al. Stiplatelet production by a single dose of recombinant human thrombopoietin in patients with cancer[J]. Ann Intern Med, 1997, 126(9): 678-681.
  • 10NICHOL JL, HOKON MM, HORNKOHI A, et al. Megakaryocyte growth and development factor. Analysis of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia[J]. J Clin Invest, 1995, 95(6) : 2973-2978.

引证文献3

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部